

Gerard J Criner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7787574/publications.pdf>

Version: 2024-02-01

187
papers

15,141
citations

36303

51
h-index

19749

117
g-index

191
all docs

191
docs citations

191
times ranked

13896
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	5.6	2,393
2	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
3	Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine, 2011, 155, 179.	3.9	896
4	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine, 2018, 378, 1671-1680.	27.0	823
5	A Randomized Study of Endobronchial Valves for Advanced Emphysema. New England Journal of Medicine, 2010, 363, 1233-1244.	27.0	704
6	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 24-36.	5.6	417
7	Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2017, 377, 1613-1629.	27.0	397
8	Chronic Bronchitis and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 228-237.	5.6	334
9	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstruccion Crónica: Resumen Ejecutivo de GOLD. Archivos De Bronconeumología, 2017, 53, 128-149.	0.8	312
10	Sex Differences in Severe Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 243-252.	5.6	301
11	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	2.3	299
12	The Chronic Bronchitic Phenotype of COPD. Chest, 2011, 140, 626-633.	0.8	280
13	Cigarette Smoke Silences Innate Lymphoid Cell Function and Facilitates an Exacerbated Type I Interleukin-33-Dependent Response to Infection. Immunity, 2015, 42, 566-579.	14.3	263
14	A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1151-1164.	5.6	253
15	Prevention of Acute Exacerbations of COPD. Chest, 2015, 147, 894-942.	0.8	230
16	Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 324-330.	5.6	221
17	Treatment of Persistent Pulmonary Air Leaks Using Endobronchial Valves. Chest, 2009, 136, 355-360.	0.8	208
18	Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema. JAMA - Journal of the American Medical Association, 2016, 315, 2178.	7.4	208

#	ARTICLE	IF	CITATIONS
19	The National Emphysema Treatment Trial (NETT). American Journal of Respiratory and Critical Care Medicine, 2011, 184, 881-893.	5.6	180
20	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	27.0	180
21	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516.	5.6	151
22	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	5.6	121
23	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respiratory Medicine, the, 2019, 7, 487-496.	10.7	119
24	From GOLD 0 to Pre-COPD. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 414-423.	5.6	119
25	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	5.6	111
26	Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 575-581.	5.6	110
27	A randomised trial of lung sealant <i>versus</i> medical therapy for advanced emphysema. European Respiratory Journal, 2015, 46, 651-662.	6.7	105
28	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA - Journal of the American Medical Association, 2020, 323, 2268.	7.4	104
29	Biologic Lung Volume Reduction in Advanced Upper Lobe Emphysema. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 791-798.	5.6	103
30	Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1354-1362.	5.6	97
31	Expert Statement: Pneumothorax Associated with Endoscopic Valve Therapy for Emphysema - Potential Mechanisms, Treatment Algorithm, and Case Examples. Respiration, 2014, 87, 513-521.	2.6	92
32	Effect of Lung Volume Reduction Surgery on Diaphragm Strength. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1578-1585.	5.6	88
33	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	3.5	88
34	CT Metrics of Airway Disease and Emphysema in Severe COPD. Chest, 2009, 136, 396-404.	0.8	87
35	Effect of Lung Volume Reduction Surgery on Resting Pulmonary Hemodynamics in Severe Emphysema. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 253-260.	5.6	81
36	Functional interactors of three genome-wide association study genes are differentially expressed in severe chronic obstructive pulmonary disease lung tissue. Scientific Reports, 2017, 7, 44232.	3.3	76

#	ARTICLE	IF	CITATIONS
37	Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. <i>European Respiratory Journal</i> , 2014, 43, 387-396.	6.7	73
38	DNA methylation profiling in human lung tissue identifies genes associated with COPD. <i>Epigenetics</i> , 2016, 11, 730-739.	2.7	73
39	Endoscopic Lung Volume Reduction: An Expert Panel Recommendation – Update 2019. <i>Respiration</i> , 2019, 97, 548-557.	2.6	72
40	Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD. <i>Chest</i> , 2014, 146, 941-950.	0.8	71
41	Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 957-968.	5.6	71
42	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. <i>Lancet Respiratory Medicine</i> , 2020, 8, 158-170.	10.7	69
43	The clinical impact of non-obstructive chronic bronchitis in current and former smokers. <i>Respiratory Medicine</i> , 2014, 108, 491-499.	2.9	65
44	Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000650.	3.0	64
45	Reconsidering the Utility of Race-Specific Lung Function Prediction Equations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 819-829.	5.6	63
46	Racial Differences in Quality of Life in Patients With COPD. <i>Chest</i> , 2011, 140, 1169-1176.	0.8	61
47	Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1280-1287.	3.2	60
48	Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 464-472.	5.6	59
49	Effect of Emphysema Severity on the Apnea-Hypopnea Index in Smokers with Obstructive Sleep Apnea. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1129-1135.	3.2	57
50	Human Lung DNA Methylation Quantitative Trait Loci Colocalize with Chronic Obstructive Pulmonary Disease Genome-Wide Association Loci. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1275-1284.	5.6	56
51	Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2017. <i>Respiration</i> , 2017, 94, 380-388.	2.6	55
52	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 211-220.	5.6	55
53	Preventing Acute Exacerbations and Hospital Admissions in COPD. <i>Chest</i> , 2013, 143, 1444-1454.	0.8	52
54	Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. <i>Respiratory Medicine</i> , 2014, 108, 722-728.	2.9	52

#	ARTICLE	IF	CITATIONS
55	Interventional Bronchoscopy. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 29-50.	5.6	52
56	National Emphysema Treatment Trial: The Major Outcomes of Lung Volume Reduction Surgery in Severe Emphysema. Proceedings of the American Thoracic Society, 2008, 5, 393-405.	3.5	51
57	Executive Summary. Chest, 2015, 147, 883-893.	0.8	51
58	Heart Failure and Respiratory Hospitalizations Are Reduced in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease With the Use of an Implantable Pulmonary Artery Pressure Monitoring Device. Journal of Cardiac Failure, 2015, 21, 240-249.	1.7	50
59	Submassive Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 588-598.	5.6	50
60	The National Emphysema Treatment Trial (NETT). American Journal of Respiratory and Critical Care Medicine, 2011, 184, 763-770.	5.6	49
61	Chronic Bronchitis and Current Smoking Are Associated with More Goblet Cells in Moderate to Severe COPD and Smokers without Airflow Obstruction. PLoS ONE, 2015, 10, e0116108.	2.5	48
62	Mitochondrial dysfunction in human primary alveolar type II cells in emphysema. EBioMedicine, 2019, 46, 305-316.	6.1	46
63	Analysis of Asthma-€"Chronic Obstructive Pulmonary Disease Overlap Syndrome Defined on the Basis of Bronchodilator Response and Degree of Emphysema. Annals of the American Thoracic Society, 2016, 13, 1483-1489.	3.2	44
64	Surgical Approaches to Treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and Lung Transplantation. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 592-608.	2.1	43
65	The Oral-Lung Axis: The Impact of Oral Health on Lung Health. Respiratory Care, 2020, 65, 1211-1220.	1.6	43
66	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2021, 325, 1841.	7.4	43
67	A Telemedicine-Based Intervention Reduces the Frequency and Severity of COPD Exacerbation Symptoms: A Randomized, Controlled Trial. Telemedicine Journal and E-Health, 2016, 22, 114-122.	2.8	42
68	A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 721-731.	5.6	40
69	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 987-997.	5.6	38
70	Activation and polarization of circulating monocytes in severe chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2018, 18, 101.	2.0	37
71	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight, 2020, 5, .	5.0	37
72	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2016, 13, 1016-1025.	3.2	36

#	ARTICLE	IF	CITATIONS
73	COVID-19 in lung transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13364.	1.7	36
74	Race and Gender Disparities are Evident in COPD Underdiagnoses Across all Severities of Measured Airflow Obstruction. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 177-184.	0.7	36
75	Multiplanar MDCT measurement of esophageal hiatus surface area: association with hiatal hernia and GERD. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 2465-2472.	2.4	35
76	Ensemble genomic analysis in human lung tissue identifies novel genes for chronic obstructive pulmonary disease. <i>Human Genomics</i> , 2018, 12, 1.	2.9	35
77	miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation. <i>ERJ Open Research</i> , 2019, 5, 00138-2019.	2.6	35
78	Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD. <i>Chest</i> , 2020, 157, 856-865.	0.8	35
79	Sleep disruption as a predictor of quality of life among patients in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS). <i>Sleep</i> , 2018, 41, .	1.1	33
80	Clinical characteristics and prediction of pulmonary hypertension in severe emphysema. <i>Respiratory Medicine</i> , 2014, 108, 482-490.	2.9	32
81	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 636-642.	3.2	30
82	Venoarterial Extracorporeal Membrane Oxygenation in Massive Pulmonary Embolism-Related Cardiac Arrest: A Systematic Review*. <i>Critical Care Medicine</i> , 2021, 49, 760-769.	0.9	30
83	Ambulatory Home Oxygen: What Is the Evidence for Benefit, and Who Does It Help?. <i>Respiratory Care</i> , 2013, 58, 48-64.	1.6	29
84	Non-pharmacological treatments for COPD. <i>Respirology</i> , 2016, 21, 791-809.	2.3	29
85	β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βBLOCK) Tj ETQq1 1 0.784314rgBT /C 1.9 29	1.9	29
86	Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced Emphysema. <i>Chest</i> , 2019, 155, 928-937.	0.8	29
87	Incidence of venous thromboembolism in coronavirus disease 2019: An experience from a single large academic center. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 585-591.e2.	1.6	29
88	Risk Factors for Venous Thromboembolism in Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 1, 239-249.	0.7	28
89	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1237-1243.	5.6	28
90	Optimizing the 6-Min Walk Test as a Measure of Exercise Capacity in COPD. <i>Chest</i> , 2012, 142, 1545-1552.	0.8	27

#	ARTICLE	IF	CITATIONS
91	The effect of cysteine oxidation on DJ-1 cytoprotective function in human alveolar type II cells. <i>Cell Death and Disease</i> , 2019, 10, 638.	6.3	27
92	Air Current Applied to the Face Improves Exercise Performance in Patients with COPD. <i>Lung</i> , 2015, 193, 725-731.	3.3	26
93	Simultaneous LC-MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. <i>Biomedical Chromatography</i> , 2018, 32, e4102.	1.7	26
94	Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 389.	2.3	23
95	The role of DJ-1 in human primary alveolar type II cell injury induced by e-cigarette aerosol. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 317, L475-L485.	2.9	23
96	Efficacy of Tiotropium Inhalation Powder in African-American Patients with Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 35-41.	1.6	22
97	Preventing clinically important deterioration with single-inhaler triple therapy in COPD. <i>ERJ Open Research</i> , 2018, 4, 00047-2018.	2.6	22
98	Radiological correlates and clinical implications of the paradoxical lung function response to β_2 agonists: an observational study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 911-918.	10.7	21
99	Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. <i>Respiratory Medicine</i> , 2019, 147, 37-43.	2.9	21
100	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 313-323.	5.6	21
101	Expert Statement: Pneumothorax Associated with One-Way Valve Therapy for Emphysema: 2020 Update. <i>Respiration</i> , 2021, 100, 969-978.	2.6	20
102	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. <i>Annals of the American Thoracic Society</i> , 2021, 18, 788-798.	3.2	19
103	Anti-Granulocyte Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1290-1299.	5.6	19
104	Alternatives to Lung Transplantation: Lung Volume Reduction for COPD. <i>Clinics in Chest Medicine</i> , 2011, 32, 379-397.	2.1	18
105	Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. <i>Chest</i> , 2018, 154, 266-273.	0.8	18
106	Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS. <i>Chest</i> , 2019, 155, 908-917.	0.8	18
107	Measuring disease activity in COPD: is clinically important deterioration the answer?. <i>Respiratory Research</i> , 2020, 21, 134.	3.6	18
108	A Clinician's Guide to the Use of Lung Volume Reduction Surgery. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 461-467.	3.5	17

#	ARTICLE	IF	CITATIONS
109	Genomics and response to long-term oxygen therapy in chronic obstructive pulmonary disease. <i>Journal of Molecular Medicine</i> , 2018, 96, 1375-1385.	3.9	17
110	Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2020, 17, 829-838.	3.2	17
111	Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 536-545.	5.6	17
112	Efficacy and safety of virtual bronchoscopic navigation with fused fluoroscopy and vessel mapping for access of pulmonary lesions. <i>Respirology</i> , 2022, 27, 357-365.	2.3	16
113	Daily Peak Expiratory Flow Rate and Disease Instability in Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 398-405.	0.7	15
114	The cytoprotective role of DJ-1 and p45 NFE2 against human primary alveolar type II cell injury and emphysema. <i>Scientific Reports</i> , 2018, 8, 3555.	3.3	15
115	Examining ABO Compatible Donors in Double Lung Transplants During the Era of Lung Allocation Score. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1167-1174.	1.3	14
116	Single-lung transplantation with ABO-compatible donors results in excellent outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 822-828.	0.6	14
117	Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. <i>Scientific Reports</i> , 2020, 10, 10562.	3.3	14
118	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. <i>Respiratory Research</i> , 2021, 22, 126.	3.6	14
119	Lung proteomic biomarkers associated with chronic obstructive pulmonary disease. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L1119-L1130.	2.9	14
120	Care of the patient requiring invasive mechanical ventilation. <i>Respiratory Care Clinics of North America</i> , 2002, 8, 575-592.	0.5	13
121	Impaired non-homologous end joining in human primary alveolar type II cells in emphysema. <i>Scientific Reports</i> , 2019, 9, 920.	3.3	13
122	Mobilization and Preparation of a Large Urban Academic Center during the COVID-19 Pandemic. <i>Annals of the American Thoracic Society</i> , 2020, 17, 922-925.	3.2	13
123	Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2015, 15, 111.	2.0	12
124	Use of a SmartPhone/Tablet-Based Bidirectional Telemedicine Disease Management Program Facilitates Early Detection and Treatment of COPD Exacerbation Symptoms. <i>Telemedicine Journal and E-Health</i> , 2016, 22, 395-399.	2.8	12
125	Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 838-845.	5.6	12
126	Lung Volume Reduction Surgery and Lung Volume Reduction in Advanced Emphysema: Who and Why?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 348-364.	2.1	10

#	ARTICLE	IF	CITATIONS
127	Sonographic Evaluation of Diaphragmatic Dysfunction. <i>Journal of Thoracic Imaging</i> , 2019, 34, W131-W140.	1.5	9
128	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. <i>Respiratory Research</i> , 2020, 21, 139.	3.6	9
129	Utility of the ROX Index in Predicting Intubation for Patients With COVID-19-Related Hypoxemic Respiratory Failure Receiving High-Flow Nasal Therapy: Retrospective Cohort Study. <i>Jmirx Med</i> , 2021, 2, e29062.	0.4	9
130	Dose-Response Characteristics of Nebulized Albuterol in the Treatment of Acutely Ill, Hospitalized Asthmatics. <i>Journal of Asthma</i> , 1999, 36, 539-546.	1.7	8
131	Long-term ventilation introduction and perspectives. <i>Respiratory Care Clinics of North America</i> , 2002, 8, 345-353.	0.5	8
132	The Role of Noninvasive Ventilation in the Management and Mitigation of Exacerbations and Hospital Admissions/Readmissions for the Patient With Moderate to Severe COPD (Multimedia Activity). <i>Chest</i> , 2015, 147, 1704-1705.	0.8	8
133	The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. <i>Annals of the American Thoracic Society</i> , 2018, 15, 89-101.	3.2	8
134	Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1296-1303.	3.2	8
135	The relationship between DJ-1 and S100A8 in human primary alveolar type II cells in emphysema. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 317, L791-L804.	2.9	8
136	Inflammatory signature in lung tissues in patients with combined pulmonary fibrosis and emphysema. <i>Biomarkers</i> , 2019, 24, 232-239.	1.9	8
137	Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life. <i>Chest</i> , 2020, 158, 529-538.	0.8	8
138	High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV) for Stable Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients - See more at: http://journal.copdfoundation.org/#sthash.CDAuozRw.dpuf . <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015, 2, 313-320.	0.7	8
139	Effect of Bilateral Lung Volume Reduction Surgery on FEV ₁ Decline in Severe Emphysema. COPD: <i>Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 203-208.	1.6	7
140	Characteristics at the time of oxygen initiation associated with its adherence: Findings from the COPD Long-term Oxygen Treatment Trial. <i>Respiratory Medicine</i> , 2019, 149, 52-58.	2.9	7
141	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. <i>ERJ Open Research</i> , 2021, 7, 00663-2020.	2.6	7
142	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 97.	3.6	7
143	Meta-analysis and Systematic Review of Bronchoscopic Lung Volume Reduction Through Endobronchial Valves in Severe Emphysema. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2022, 29, 224-237.	1.4	7
144	The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPD. <i>Journal of Clinical Medicine</i> , 2020, 9, 3832.	2.4	6

#	ARTICLE	IF	CITATIONS
145	Bronchoscopic lung volume reduction: status quo. <i>Annals of Translational Medicine</i> , 2020, 8, 1469-1469.	1.7	6
146	Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2021, 22, 316.	3.6	6
147	The Role of Lobe Selection on FEV ₁ Response in Endobronchial Valve Therapy. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 477-482.	1.6	5
148	Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 125-132.	2.5	5
149	Defining Resilience to Smoking Related Lung Disease: A Modified Delphi Approach from SPIROMICS. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1822-1831.	3.2	5
150	Use of a Digital Chronic Obstructive Pulmonary Disease Respiratory Tracker in a Primary Care Setting: A Feasibility Study. <i>Pulmonary Therapy</i> , 2021, 7, 533-547.	2.2	5
151	Role of Imaging in Bronchoscopic Lung Volume Reduction Using Endobronchial Valve. <i>Journal of Thoracic Imaging</i> , 2021, 36, 131-141.	1.5	5
152	Microarray analysis identifies defects in regenerative and immune response pathways in COPD airway basal cells. <i>ERJ Open Research</i> , 2020, 6, 00656-2020.	2.6	5
153	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 370-381.	0.7	5
154	Surgery for severe COPD. <i>Postgraduate Medicine</i> , 1998, 103, 179-202.	2.0	4
155	Reduced dynamic hyperinflation after LVRS is associated with improved exercise tolerance. <i>Respiratory Medicine</i> , 2014, 108, 1491-1497.	2.9	4
156	Interventional Bronchoscopic Therapies for Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 547-557.	2.1	4
157	Rheumatologists and Pulmonologists at Temple University Weather the COVID-19 Storm Together. <i>Journal of Rheumatology</i> , 2020, 47, 1723.1-1723.	2.0	4
158	Risk of Death by Comorbidity Prompting Rehospitalization Following the Initial COPD Hospitalization. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 2, 17-22.	0.7	4
159	Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care. <i>Postgraduate Medicine</i> , 2017, 129, 725-733.	2.0	3
160	Azithromycin and risk of COPD exacerbations in patients with and without <i>Helicobacter pylori</i> . <i>Respiratory Research</i> , 2017, 18, 109.	3.6	3
161	Expression of SARS-CoV-2 Entry Factors in Human Alveolar Type II Cells in Aging and Emphysema. <i>Biomedicines</i> , 2021, 9, 779.	3.2	3
162	HLA-C and KIR permutations influence chronic obstructive pulmonary disease risk. <i>JCI Insight</i> , 2021, 6, .	5.0	3

#	ARTICLE	IF	CITATIONS
163	Is Methicillin-Resistant Staphylococcus Aureus Colonization Associated with Worse Outcomes in COPD Hospitalizations?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 252-258.	0.7	3
164	Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials. Proceedings of the American Thoracic Society, 2007, 4, 171-175.	3.5	2
165	Could digital health applications improve the health of COPD patients?. Expert Review of Respiratory Medicine, 2016, 10, 377-378.	2.5	2
166	Patient Preferences for Endobronchial Valve Treatment of Severe Emphysema. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 6, 51-63.	0.7	2
167	Device profile of the Zephyr endobronchial valve in heterogenous emphysema: overview of its safety and efficacy. Expert Review of Medical Devices, 2021, 18, 823-832.	2.8	2
168	Effects of Roflumilast on Rehospitalization and Mortality in Patients. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 74-85.	0.7	2
169	Feasibility of Using Daily Home High-Flow Nasal Therapy in COPD Patients Following a Recent COPD Hospitalization. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, 9, 4-14.	0.7	2
170	Reply to Jain <i>et al.</i>: Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System: Still a Great Need to "EMPROVE". American Journal of Respiratory and Critical Care Medicine, 2020, 201, 391-392.	5.6	1
171	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. Chest, 2020, 157, 1391-1392.	0.8	1
172	Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium+olodaterol. Current Medical Research and Opinion, 2021, 37, 275-284.	1.9	1
173	Outcomes of COPD Exacerbations Treated with Corticosteroids, Antibiotics, or Both. ISRN Pulmonology, 2011, 2011, 1-6.	0.3	1
174	Editorial: Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 91-93.	0.7	1
175	Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 221-228.	0.7	1
176	Effect of Lung Volume Reduction Surgery on Respiratory Muscle Strength in Advanced Emphysema. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 40-50.	0.7	1
177	Tolerability and Safety of High-Flow Nasal Therapy in Patients Hospitalized with an Exacerbation of COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 362-369.	0.7	1
178	Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, , .	0.7	1
179	Advanced COPD: Pathogenesis, Evaluation, and Treatment. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 255-255.	2.1	0
180	Lung volume reduction surgery for the treatment of advanced emphysema. , 0, , 69-85.		0

#	ARTICLE	IF	CITATIONS
181	Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 219-229.	0.7	0
182	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 326-335.	0.7	0
183	Bronchoscopic Lung Volume Reduction with Zephyr Valves for Severe Emphysema. <i>Respiration</i> , 2021, 100, 1-3.	2.6	0
184	Authors'™ Responses to Peer Reviews of "Utility of the ROX Index in Predicting Intubation for Patients With COVID-19-Related Hypoxemic Respiratory Failure Receiving High-Flow Nasal Therapy: Retrospective Cohort Study". <i>Jmirx Med</i> , 2021, 2, e31892.	0.4	0
185	Hospitalizations and ED Visits in COPD: A Collision of Socioeconomic Realities with Chronic Comorbid Medical Illnesses. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 509-511.	0.7	0
186	Changes in Lung Perfusion in Patients Treated with Percutaneous Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism. <i>American Journal of Medicine</i> , 2022, , .	1.5	0
187	Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.8	0